Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 4Phase 1/2 2Phase 1 2

Status

Completed 25Unknown 14Recruiting 5Terminated 4Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Leukemia 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 48Radiotherapy 47Docetaxel 41Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Drug Therapy 14Irinotecan 13Imatinib Mesylate 13Filgrastim 13Zoledronic Acid 12Radiosurgery 12Erlotinib Hydrochloride 12Trastuzumab 11Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Idarubicin × Clear all
NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Delta-Fly Pharma, Inc.

Phase 3 Terminated
167 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04778397 2025-02-05

ENHANCE-2

Gilead Sciences

Phase 3 Terminated
258 enrolled 25 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02703272 2022-12-02

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Janssen Research & Development, LLC

Phase 3 Terminated
72 enrolled 36 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT00187005 2011-03-30

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

St. Jude Children's Research Hospital

Phase 3 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡